Skoči na glavni sadržaj

Pregledni rad


Lana Tambić Bukovac
Marija Perica

Puni tekst: hrvatski pdf 111 Kb

preuzimanja: 3.265



Juvenile idiopathic arthritis (JIA) is the most common rheumatic disorder in children and one of the
most common causes of part-time or long-term disability. Th e term juvenile idiopathic arthritis defi nes the main characteristics
of the disease: joint infl ammation of unknown origin manifested before the 16th birthday and lasting for more
than six weeks. JIA is very rare in infancy, with highest frequency in preschool age. It is not a single disease, but a group
of disorders with some common features of diff erent immunopathogenesis and with diff erent clinical manifestations. According
to the revised International League of Associations for Rheumatology (ILAR) criteria, JIA is classifi ed into 8
subtypes, but this classifi cation is still a “work in progress“ because with new knowledge gained in genetics and immunology,
the classifi cation will obviously have to be changed and refi ned. New research of the disease pathogenesis is the basis
for the development of new and better treatments for JIA. Th e goal of such treatments is not just to relieve pain, but also
to control infl ammation and stop irreversible joint damage and long-term disability. Biological agents have signifi cantly
improved the disease prognosis.

Ključne riječi

Arthritis, juvenile – classifi cation, diagnosis, drug therapy, genetics, immunolog; antirheumatic agents – therapeutic use; Adrenal cortex hormones – therapeutic use; Biological products – therapeutic use

Hrčak ID:



Datum izdavanja:


Podaci na drugim jezicima: hrvatski

Posjeta: 5.135 *